Future treatment options for HCV: Double, triple, what is the optimal combination?

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 6, 2008, Pages 1123-1136

  Kronenberger, Bernd ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

drug resistance, viral; hepatitis C virus; interferon alfa; polymerase inhibitors, HCV; protease inhibitors, HCV; ribavirin; STAT C

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CILUPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; GS 9190; ITMN 191; NM 107; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENYLALANINE DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; R 7128; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; THIOPENE 2 CARBOXYLIC ACID; THIOPHENE DERIVATIVE; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALOPICITABINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; CYTIDINE; DNA-DIRECTED RNA POLYMERASES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; NUCLEOSIDES; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PRODRUGS; PROLINE; PROTEASE INHIBITORS; PYRIMIDINE NUCLEOSIDES; RIBAVIRIN;

EID: 58949097574     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.12.002     Document Type: Article

References (36)

1. Meylan E., Curran J., Hofmann K., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
2. Li K., Foy E., Ferreon J.C., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102 (2005) 2992-2997
3. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
4. Hinrichsen H., Benhamou Y., Wedemeyer H., et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
5. Perni R.B., Almquist S.J., Byrn R.A., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50 (2006) 899-909
6. Reesink H.W., Zeuzem S., Weegink C.J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
7. Sarrazin C., Kieffer T.L., Bartels D., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 (2007) 1767-1777
8. Forestier N., Reesink H.W., Weegink C.J., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 (2007) 640-648
9. Kieffer T.L., Sarrazin C., Miller J.S., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46 (2007) 631-639
10. McHutchison J., Everson G., Gordon S.C., et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment naive-subjects with hepatitis C. J Hepatol 48 (2008) 4A
11. Dusheiko G.M., Hezode C., Pol S., et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon alfa-2a with or without ribavirin: further interim analysis results of the prove 2 study. J Hepatol 48 (2008) 26A
12. Malcolm B.A., Liu R., Lahser F., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50 (2006) 1013-1020
13. Sarrazin C., Rouzier R., Wagner F., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132 (2007) 1270-1278
14. Susser S., Welker M., Zettler M., et al. Clonal analysis of mutations selected in the HCV NS3 protease domain of genotype 1 non-responders treated with boceprevir. J Hepatol 48 (2008) 29A
15. Kwo P.Y., Lawitz E., McCone J., et al. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus peginterferon alfa-2b/ribavirin in treatment naive subjects with genotype-1 CHC. J Hepatol 48 (2008) 372A
16. Seiwert S.D., Andrews S.W., Tan H., et al. 750 preclinical characteristics of ITMN-B, an orally active inhibitor of the HCV NS3/4A protease nominated for preclinical development. J Hepatol 44 (2006) 278A
17. InterMune. InterMune submits CTA amendment for ITMN-191 and provides update on clinical development program (2007). [accessed July 24], Ref Type: Electronic Citation
18. Reesink H., Verloes R., Abou Farha K., et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a phase 1 study. J Hepatol 48 (2008) 28A
19. Pierra C., Amador A., Benzaria S., et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 49 (2006) 6614-6620
20. Zhou X.J., Afdhal N., Godofsky E., et al. Pharmacokinetics and pharmacodynamics of valopicitabine (NM283), a new nucleoside HCV polymerase inhibitor: results from a phase I/II dose-escalation trial in patients with HCV-1 infection. J Hepatol 42 (2005) 229A
21. Lawitz E., Nguyen T., Younes Z., et al. Clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naive patients with HCV-1 infection: results at 24 and 48 weeks. J Hepatol 46 (2007) 9A
22. Migliaccio G., Tomassini J.E., Carroll S.S., et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278 (2003) 49164-49170
23. Ludmerer S.W., Graham D.J., Boots E., et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49 (2005) 2059-2069
24. Klumpp K., Leveque V., Le Pogam S., et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 281 (2006) 3793-3799
25. Roberts S., Cooksley G., Dore G., et al. Results from a phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology 44 (2006) 692A
26. Nelson D., Pockros P.J., Godofsky E., et al. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin. J Hepatol 48 (2008) 371A
27. Le Pogam S., Jiang W.R., Leveque V., et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351 (2006) 349-359
28. Lalezari J., Gane E., Rodriguez-Torres M., et al. Potent antiviral activity of the HCV nucleotiside polymerase inhibitor R7128 with PEG-IFN and ribavirin: Interim results of R7128 500 mg BID for 28 days. J Hepatol 48 (2008) 29A
29. Villano S., Raible D., Harper D., et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment naive patients with chronic HCV. J Hepatol 46 (2007) 24A
30. ViroPharma. Potential safety issue identified in ongoing phase 2 clinical study of HCV-796 (2007). [accessed August 10], Ref Type: Electronic Citation
31. Flisiak R., Horban A., Kierkus J., et al. The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects. Hepatology 44 (2006) 609A
32. Kaita K., Yoshida E., Kunimoto D., et al. PhII proof of concept study of celgosivir in combination with peginterferon alpha-2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients. J Hepatol 46 (2007) S56-S57
33. Lin C., Lin K., Luong Y.P., et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279 (2004) 17508-17514
34. Lin C., Gates C.A., Rao B.G., et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280 (2005) 36784-36791
35. Koev G., Dekhtyar T., Han L., et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res 73 (2007) 78-83
36. Mathy J.E., Ma S., Compton T., et al. Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 52 (2008) 3267-3275